Interview with Albert Saporta, President and CEO, Stallergenes
Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the…
Address: 101 rue de Tolbiac 75654 Paris Cedex 13 ,France
Tel: +33 (0)1 44 23 60 98
Created in 1964, the National Institute of Health and Medical Research is a public scientific and technological, under the joint supervision of the Ministry of Health and Ministry of Research.
Inserm is the only public research body entirely dedicated to French human health. In 2008 Inserm was givin the responsibility for coordinating strategic, scientific and operational biomedical research. This central role of coordinator is a natural fit due to the scientific quality of our teams, as well as our ability to deliver translational research from bench to bedside.
Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the…
As Quintiles is present in all major pharmaceutical markets worldwide, what’s the relevance of the French affiliate and what role it plays inside such a globalized organization? France is important…
When we met your Italian colleague, he noted that they had tripled their turnover in a five year period. You haven’t done badly yourself in the relatively short period of…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
See our Cookie Privacy Policy Here
